icon-account icon-glass

Venlafaxine Withdrawal and Tapering Help

Call for venlafaxine withdrawal information   


Do you want to learn how to wean off Venlafaxine or have you tried to Get Off Venlafaxine only to reinstate due to the severe Venlafaxine Withdrawals?  The Royal College of Psychiatrists have warned that coming off antidepressant can cause symptoms lasting for months and that doses should be gradually lowered over months. Venlafaxine has a high incidence of withdrawal and why we have taken a holistic approach to Venlafaxine Withdrawal for 15 years. Our success has reached 78 countries and every state of the United States. We combine a gentle Velafaxine Taper with while helping to ease symptoms so you are able to Taper Venlafaxine more comfortably. Weaning off Venlafaxine is possible and we not only assess for herb/vitamin/over-the-counter interactions with Venlafaxine, but we establish Venlafaxine Taper rates individually so you know its right for you.  CONTACT Our Experts today for a Free Consultation.



Start our Venlafaxine withdrawal program  

Our Venlafaxine weaning program is a slow taper that allows you to safely step down from Venlafaxine under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Venlafaxine until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Venlafaxine withdrawal and support well-being.*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Venlafaxine Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Venlafaxine alone, work with our Prescription Drug Experts.

Imagine being Free of Venlafaxine Dependency 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Wean off  Venlafaxine

- All-Natural Nutraceuticals to help Ease Venlafaxine Withdrawal

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

      Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only




      Michel - how to wean off Venlafaxine

      "I really appreciate the gift of being able to be off the SSRI's because of the negative side effects they had. Thank you!!!" More...

      Michel (Venlafaxine Withdrawal Success Story)

      Anna - Venlafaxine Withdrawal Success Story

      'I am drug-free now and my mind is clear and sharp. The nerve pain is much, better and my life is full. I plan to continue taking the nutrients forever." More...

      Anna (Venlafaxine Withdrawal Success Story)

      Laura - how to wean off Venlafaxine

      "I didn't know what a fighter I was until now that I look back on this past year and realize that I never once thought about quitting the program." More...

      Laura (Venlafaxine Withdrawal Success Story)

      My heartfelt thanks to all of the POINT OF RETURN team – the group of participants that provide emotional support on the forum – and most of all – to Alesandra. More...

      —Kelia (Venlafaxine Withdrawal Success Story)

                                    using a Natural Approach

      Venlafaxine withdrawal team

      Our team has survived psychoactive drug withdrawal. More...

      how to wean off Venlafaxine anywhere in the world

      We've helped people in 78 countries and in every state of the USA. More...

      Venlafaxine withdrawal - media coverage

      We have extensive media coverage; television, print, radio. More...


      Message sent, thanks!

      Venlafaxine Resource Center


      VENLAFAXINE HISTORY AND INFO  ( link | pdf )  



          Venlafaxine Info and History 

          Venlafaxine (Effexor) is an SNRI (Selective Serotonin-Norepinephrine Reuptake Inhibitor) that was introduced by Pfizer as Effexor in 1993. By 2007, Effexor was the sixth most commonly prescribed antidepressant on the U.S. market.

          Venlafaxine has a relatively short half-life that helps to explain the severity of the Discontinuation Syndrome (withdrawals) frequently experienced by patients. It is hypothesized that an overly rapid deprivation of multiple neurotransmitter levels contributes to the high rate of withdrawals.

          Venlafaxine (Effexor) can increase eye pressure so patients with glaucoma should have more frequent eye checks.  There are few well-controlled studies of Effexor in pregnant women but a study released in May 2010 (Canadian Medical Association Journal) suggested it doubled the risk of miscarriage.

          Effexor (Venlafaxine) was marketed for the use of major depression, generalized anxiety, panic disorder and social phobia. At dosages less than 150mg per day, it acts primarily on Serotonin, while at moderate dosages of 150-300mg Venlafaxine affected both Serotonin and Norepinephrine. At dosages above 300mg, Effexor also exerted it effect on Dopamine.

          Serotonin is found primarily in the gastrointestinal tract, blood platelets and central nervous system. Norepinephrine has multiple roles including as a hormone and neurotransmitter and is most responsible for vigilant concentration in contrast to Dopamine that is most responsible for cognitive alertness.  The widespread role of these neurotransmitters helps to explain the long list of possible Venlafaxine side effects and withdrawal symptoms. 

          Venlafaxine Withdrawal Symptoms, Side Effects, Adverse Reactions


          aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression


          agitation, anxiety, confusion, irritability, sensory disturbances, electric shock sensations, dysphoric mood, headache, emotional liability, insomnia, hypomania, tinnitus, seizures, impaired coordination, diarrhea, dizziness, nausea, nervousness, nightmares, somnolence, tremor, vertigo and vomiting


          abnormal dreams, abnormal ejaculation or orgasm, anxiety, appetite loss, blurred vision, chills, constipation, diarrhea, dizziness, dry mouth, frequent urination, flushing, gas, headache, impotence, infection, insomnia, muscle tension, nausea, nervousness, rash, sleepiness, sweating, tingling feeling, tremor, upset stomach, vomiting, weakness, yawning, abnormal taste, abnormal thinking, agitation, chest pain, confusion, decreased sex drive, depression, dilated pupils, dizziness upon standing up, high blood pressure, itching, loss of identity, rapid heartbeat, ringing in the ears, trauma, twitching, urinary problems, weight loss


          Severe: peptic ulcer, bradycardia, laryngospasm, exfoliative dermatitis, seizures, muscle paralysis, Guillain-Barre syndrome, torticollis, akinesia, stroke, obstruction, heart failure, myocardial infarction , AV block, hematemesis, tendon rupture, cholecystitis, pulmonary embolism, laryngeal edema , apnea, spontaneous fetal abortion, anuria, oliguria , hyperkalemia, prostatic hypertrophy, proteinuria, tardive dyskinesia, suicidal ideation, pancreatitis, ventricular tachycardia, cardiomyopathy, torsade de pointes , ventricular fibrillation, atrial fibrillation, ocular hypertension, serotonin syndrome, neuroleptic malignant syndrome, SIADH, GI bleeding, habdomyolysis, hepatic failure, hepatic necrosis, eosinophilic pneumonia, aplastic anemia , pancytopenia, agranulocytosis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), erythema multiforme, angioedema, toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylactoid reactions, renal failure (unspecified), neonatal abstinence syndrome

          Moderate: ejaculation dysfunction, constipation, hypertension, blurred vision, impotence (erectile dysfunction), hypertonia, depression, confusion , sinus tachycardia, hostility, hallucinations, psychosis, euphoria, peripheral neuropathy, akathisia, ataxia, neuropathic pain, dysarthria, neuritis, hyperesthesia, hypotonia, gastritis, stomatitis, hemorrhoids,, colitis, oral ulceration, glossitis, dysphagia, esophagitis, teeth grinding (bruxism), hypotension, orthostatic hypotension, angina, peripheral vasoconstriction, phlebitis, photophobia, conjunctivitis, cataracts, melena, bone pain, myasthenia, synovitis, hyperlipidemia, hypercholesterolemia, dysphonia, thrombocytopenia, anemia, lymphadenopathy, leukopenia, psoriasis, contact dermatitis, urinary incontinence, vaginal bleeding, urinary retention, hypokalemia, hyperglycemia, withdrawal, mania, impulse control symptoms, dystonic reaction, paresis, aphasia, hyperreflexia, nystagmus, parotitis , proctitis, bundle-branch block, hyponatremia, prolonged bleeding time, hepatitis, jaundice, cholelithiasis, hypoventilation, hemoptysis, hypoxia , lymphocytosis, eosinophilia, flank pain, hypercalciuria, glycosuria, nephrolithiasis, hyperthyroidism, galactorrhea, goiter, hypothyroidism, hypophosphatemia, diabetes mellitus, hyperuricemia, hyperphosphatemia, hypoglycemia, gout, amnesia, trismus, chest pain (unspecified), edema, vaginitis, prostatitis, delirium, dyskinesia, supraventricular tachycardia (SVT), QT prolongation, growth inhibition, priapism, bleeding, platelet dysfunction, elevated hepatic enzymes, steatosis, dyspnea, neutropenia, hyperprolactinemia

          Mild: nausea, weight loss, headache, insomnia, drowsiness, xerostomia, dizziness, hyperhidrosis, weakness, anorexia, asthenia, yawning, diarrhea, libido decrease, dyspepsia, anxiety, vomiting, infection, tremor, orgasm dysfunction, flushing, agitation, paresthesias, flatulence, rash, increased urinary frequency, chills, emotional lability, hyperkinesis, gingivitis, syncope, xerophthalmia, diplopia, arthralgia, muscle cramps, epistaxis.  hyperventilation, laryngitis, leukocytosis, acne vulgaris, maculopapular rash, urticaria, alopecia, xerosis, pruritus, photosensitivity, hirsutism, urinary urgency , nocturia, polyuria, menorrhagia, amenorrhea, mastalgia, fever, paranoia, hyporeflexia, tongue discoloration, cheilitis, hypersalivation, pallor, petechiae , purpura, breast enlargement, gynecomastia, breast discharge, vertigo, dysgeusia, eructation, mydriasis, menstrual irregularity, restlessness, night sweats, ecchymosis, cough


          Children, growth inhibition, suicidal ideation

          Venlafaxine is not FDA approved for the treatment of major depressive disorder (MDD) in children. In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with venlafaxine. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose. Postmarketing data suggest that overdose with venlafaxine may result in more serious outcomes (i.e., fatalities) compared to selective serotonin reuptake inhibitors (SSRIs), but less than for tricyclic antidepressants (TCAs). Most reports of overdose have included ingestion of a combination of drugs, including alcohol. Venlafaxine has been shown to lead to dose-dependent weight loss in children ages 6 to 17 years. In addition, growth inhibition has been noted in short and long-term studies in children. Clinicians should regularly monitor height and weight changes in pediatric patients receiving venlafaxine.  

          Venlafaxine References and Information 

          According to the FDA:

          Serotonin Syndrome: Risk increases with concomitant use of other serotonergic drugs. Discontinue Effexor XR and initiate supportive treatment if serotonin syndrome occurs

          Discontinuation [Symptoms]

          Advise patients not to stop taking Effexor XR without talking first with their healthcare professional. Patients should be aware that discontinuation effects may occur when stopping Effexor XR [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)]. When discontinuing treatment, reduce the dose gradually (2.8, 5.7).


          *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

          *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

          * Testimonial results may vary person to person.

          *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

          *This program is not meant to cure or prevent any disease or illness.

          *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..